An evaluation of a new lactic acid polymer drug delivery system: a preliminary report.
A new drug delivery system, made of a mixture of DL-lactic acid polymer and a copoly (L-lactic acid/delta-valerolactone) polymer (LAP) containing varying concentrations of Ofloxacin, has been evaluated. Results revealed that a LAP drug delivery system containing 0.03% Ofloxacin inhibited the in vitro growth of clinically derived Staphylococcus aureus and Pseudomonas aeruginosa. Further, in an in vivo situation in rats, at 1 week after the wound was inflicted, no infection was macroscopically seen in split-thickness wounds that had been covered by LAP drug delivery system containing 0.5 or 0.03% Ofloxacin, and more than 80% of the wound area had epithelialised.
Sawada
Y
Y
Department of Plastic and Reconstructive Surgery, Hirosaki University School of Medicine, Japan.
Ohkubo
T
T
Kudoh
M
M
Sugawara
K
K
Otani
K
K
Sasaki
J
J
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D007773:Lactates; D019344:Lactic Acid; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D011091:Polyesters; D011108:Polymers; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000254:growth & development; D011753:Pyrones; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D014946:Wound Infection / Q000517:prevention & control
D007773:Lactates; D011091:Polyesters; D011108:Polymers; D011753:Pyrones; C052207:delta-valerolactone; D019344:Lactic Acid; C033616:poly(lactide); D015242:Ofloxacin